Waeber B, Roth D
Division d'Hypertension, CHUV, Lausanne.
Praxis (Bern 1994). 1995 Nov 28;84(48):1432-4.
The HOT study (hypertension-optimal treatment) is an international clinical study on primary prevention of cardiovascular events in 19,193 hypertensive patients worldwide. It aims at the recognition of the optimal diastolic blood pressure value (< 90, < 85 or < 80 mmHg?) in order to maximize the possible benefit of an antihypertensive therapy. In addition, the HOT study investigates whether low doses of aspirin (75 mg/day) are able to reduce the occurrence of severe cardiovascular events. In Switzerland a total of 797 patients have been enrolled in the study. Antihypertensive therapy was initiated with felodipine = Plendil (5 mg/day). This vasoelective calcium antagonist could reduce diastolic blood pressure values to < 90 or < 80 mg/Hg, respectively, in one of two or one of three patients within the first three months. In nine or six patients, respectively out of ten a reduction of diastolic blood pressure values to < 90 or < 80 mmHg was reached within one year by combination of felodipine with other antihypertensive drugs (ACE inhibitors, beta blockers and diuretics).
HOT研究（高血压最佳治疗研究）是一项针对全球19193名高血压患者进行心血管事件一级预防的国际临床研究。其目的是确定最佳舒张压值（<90、<85还是<80 mmHg？），以便使抗高血压治疗的潜在益处最大化。此外，HOT研究还调查了小剂量阿司匹林（75毫克/天）是否能够降低严重心血管事件的发生率。在瑞士，共有797名患者参与了该研究。抗高血压治疗起始用药为非洛地平（波依定，5毫克/天）。这种血管选择性钙拮抗剂在前三个月内分别能使三分之二或三分之一的患者舒张压值降至<90或<80 mmHg。通过非洛地平与其他抗高血压药物（血管紧张素转换酶抑制剂、β受体阻滞剂和利尿剂）联合使用，分别能使十分之九或十分之六的患者在一年内舒张压值降至<90或<80 mmHg。
